NCT00341354

Brief Summary

This study, conducted at the San Gerardo Hospital in Milan, Italy, will examine whether a bacteriocidal-coated endotracheal tube (breathing tube) cleaned with a device called a Mucus Shaver is safe and effective in preventing hospital-acquired infections in patients who require prolonged mechanical ventilation in an intensive care unit (ICU). Pneumonia is the most frequent hospital-acquired infection in the ICU; its development is likely related to the use of a breathing tube. The tube is placed in the patient's trachea (windpipe) to assist breathing during and after an operation. Currently, breathing tubes in intubated patients are cleaned with a suction catheter that draws out secretions that accumulate in the tube. This method does not clean the tube completely, however, and within a few hours after the breathing tube is placed, bacteria may begin to grow inside the tube. Over time, as the patient breathes in and out through the tube, the bacteria may break free and enter the lungs, possibly causing pneumonia. In addition, the growth of bacteria in the tube decreases the size of the airway passage, making it more difficult to keep air moving in and out of the lungs. Previous studies have shown that breathing tubes coated with silver-sulfadiazine prevented bacterial growth in the patient's airways and that use of the Mucus Shaver prevented accumulation of secretions in the lumen of the breathing tube, keeping the tube open. This study will determine if use of the coated tube and Mucus Shaver in patients requiring prolonged mechanical ventilation is safe and if it can reduce bacterial growth, the length of intubation and mechanical ventilation, the occurrence of pneumonia and the length of time in ICU and hospital. Patients at San Gerardo Hospital who are 18 and older, who expect to have a breathing tube in place for more than 48 hours, and who are not allergic to silver-sulfadiazine may be eligible for this study. Participants are randomly assigned to have either a standard breathing tube and standard cleaning or a coated tube cleaned with a Mucus Shaver. At intubation, a sample of secretions is collected from the mouth, the lumen of the breathing tube, and the airways. The lumen of the breathing tube is then cultured every day. When the tube is removed, or on the eighth day of intubation, a sample of secretions is collected from the mouth, the lumen of the breathing tube, and the airways. After the tube is removed, it is examined for biological and microscopic analysis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Jan 2006

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 27, 2006

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

June 19, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 21, 2006

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 6, 2007

Completed
Last Updated

July 2, 2017

Status Verified

September 6, 2007

First QC Date

June 19, 2006

Last Update Submit

June 30, 2017

Conditions

Keywords

PneumoniaBacterial InfectionNosocomial InfectionTracheaBiofilmMucus Shaver

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females greater than 18 years old;
  • Patients who are expected to be intubated and mechanically ventilated for greater than 48 hours;
  • Patients who require an endotracheal tube with an internal diameter of 7.5 mm or 8.0 mm.

You may not qualify if:

  • Males and females less than 18 years old;
  • Patients who are expected to be intubated for less than 48 hours;
  • Patients who are allergic to silver-sulfadiazine;
  • Patients who require an internal diameter of an endotracheal tube less than 7.5 mm or greater than 8.0 mm;
  • Patients who do not tolerate disconnection from the ventilator:
  • Hemodynamically unstable;
  • Severe ARDS: PaO2/FiO2 less than or equal to 200 at PEEP less than or equal to 5 cmH20.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital San Gerardo di Monza, University of Bicocca Monza

Milan, Italy

Location

MeSH Terms

Conditions

InfectionsPneumoniaBacterial InfectionsCross InfectionTracheal Diseases

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsLung DiseasesRespiratory Tract DiseasesBacterial Infections and MycosesIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
phase 2
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

June 19, 2006

First Posted

June 21, 2006

Study Start

January 27, 2006

Study Completion

September 6, 2007

Last Updated

July 2, 2017

Record last verified: 2007-09-06

Locations